Sign In
Buy KURA
$8.66
-0.315 (-3.51%)
At Close: Jun 03, 2026
Driehaus Capital Management LLC Cuts Stake in Kura Oncology Inc (NASDAQ:KURA)
10:36am, Tuesday, 10'th Mar 2020
Driehaus Capital Management LLC lowered its position in shares of Kura Oncology Inc (NASDAQ:KURA) by 91.4% during the 4th quarter, according to the company in its most recent disclosure with the Secur
Edited Transcript of KURA earnings conference call or presentation 25-Feb-20 9:30pm GMT
07:18am, Tuesday, 10'th Mar 2020
Q4 2019 Kura Oncology Inc Earnings Call
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 9.)
Arcutis...
Rhumbline Advisers Has $580,000 Stake in Kura Oncology Inc (NASDAQ:KURA)
09:56am, Sunday, 08'th Mar 2020
Rhumbline Advisers boosted its position in shares of Kura Oncology Inc (NASDAQ:KURA) by 4.3% in the fourth quarter, Holdings Channel reports. The fund owned 42,200 shares of the company’s stock afte
Kura Oncology's tipifarnib Fast Track'd for T-cell lymphomas
02:28pm, Tuesday, 03'rd Mar 2020
The FDA has designated Kura Oncology's (NASDAQ:KURA) lead drug tipifarnib for Fast Track review for the treatment of adults with relapsed or refractory angioimmunoblastic T-cell lymphoma, follicular T
BRIEF-Kura Oncology Receives Fast Track Designation For Tipifarnib In T-Cell Lymphomas
12:33pm, Tuesday, 03'rd Mar 2020
Kura Oncology Inc:
Kura Oncology receives Fast Track designation for tipifarnib in T-cell lymphomas KURA
12:32pm, Tuesday, 03'rd Mar 2020
Kura Oncology receives Fast Track designation for tipifarnib in T-cell lymphomas KURA
Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas
12:30pm, Tuesday, 03'rd Mar 2020
Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Admini
Kura Oncology (NASDAQ:KURA) Downgraded by Zacks Investment Research to Hold
09:48am, Tuesday, 03'rd Mar 2020
Kura Oncology (NASDAQ:KURA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com report
Kura Oncology Inc (NASDAQ:KURA) to Post FY2020 Earnings of ($1.80) Per Share, Svb Leerink Forecasts
08:46am, Tuesday, 03'rd Mar 2020
Kura Oncology Inc (NASDAQ:KURA) – Investment analysts at Svb Leerink decreased their FY2020 EPS estimates for Kura Oncology in a research note issued to investors on Wednesday, February 26th. Svb Le
Wedbush Weighs in on Kura Oncology Inc's Q1 2020 Earnings (NASDAQ:KURA)
08:12am, Tuesday, 03'rd Mar 2020
Kura Oncology Inc (NASDAQ:KURA) – Analysts at Wedbush decreased their Q1 2020 earnings per share (EPS) estimates for Kura Oncology in a research report issued on Wednesday, February 26th. Wedbush an
Fmr LLC Acquires 64,213 Shares of Kura Oncology Inc (NASDAQ:KURA)
12:14pm, Monday, 02'nd Mar 2020
Fmr LLC lifted its holdings in shares of Kura Oncology Inc (NASDAQ:KURA) by 1.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm o
Brokers Set Expectations for Kura Oncology Inc's FY2022 Earnings (NASDAQ:KURA)
08:20am, Sunday, 01'st Mar 2020
Kura Oncology Inc (NASDAQ:KURA) – Research analysts at Piper Sandler cut their FY2022 EPS estimates for shares of Kura Oncology in a note issued to investors on Tuesday, February 25th. Piper Sandler
Kura Oncology Inc Forecasted to Earn FY2024 Earnings of $1.50 Per Share (NASDAQ:KURA)
11:40am, Saturday, 29'th Feb 2020
Kura Oncology Inc (NASDAQ:KURA) – Equities researchers at Piper Sandler issued their FY2024 EPS estimates for Kura Oncology in a report issued on Tuesday, February 25th. Piper Sandler analyst T. Van
FY2024 Earnings Estimate for Kura Oncology Inc Issued By Oppenheimer (NASDAQ:KURA)
10:54am, Saturday, 29'th Feb 2020
Kura Oncology Inc (NASDAQ:KURA) – Equities research analysts at Oppenheimer issued their FY2024 earnings per share estimates for Kura Oncology in a research note issued on Tuesday, February 25th. Op
